Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.

Hersh CM, Love TE, Bandyopadhyay A, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D.

Mult Scler J Exp Transl Clin. 2017 Aug 24;3(3):2055217317715485. doi: 10.1177/2055217317715485. eCollection 2017 Jul-Sep.

2.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.

Hersh CM, Love TE, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D.

Mult Scler Relat Disord. 2016 Nov;10:44-52. doi: 10.1016/j.msard.2016.08.002. Epub 2016 Aug 8.

PMID:
27919497
3.

Experience with fingolimod in clinical practice.

Hersh CM, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA, Ontaneda D.

Int J Neurosci. 2015;125(9):678-85. doi: 10.3109/00207454.2014.969839. Epub 2014 Oct 29.

4.

Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic.

Erbayat Altay E, Fisher E, Jones SE, Hara-Cleaver C, Lee JC, Rudick RA.

JAMA Neurol. 2013 Mar 1;70(3):338-44.

5.

Early tolerability and safety of fingolimod in clinical practice.

Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA.

J Neurol Sci. 2012 Dec 15;323(1-2):167-72. doi: 10.1016/j.jns.2012.09.009. Epub 2012 Oct 3.

6.

Validation of a self-report comorbidity questionnaire for multiple sclerosis.

Horton M, Rudick RA, Hara-Cleaver C, Marrie RA.

Neuroepidemiology. 2010 Aug;35(2):83-90. doi: 10.1159/000311013. Epub 2010 Jun 15.

7.

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.

Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M; ACT Investigators.

Neurology. 2009 Feb 10;72(6):535-41. doi: 10.1212/01.wnl.0000341934.12142.74.

PMID:
19204263
8.

Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.

Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H; ACT Investigators.

Mult Scler. 2008 Apr;14(3):370-82. doi: 10.1177/1352458507083189. Epub 2008 Jan 21.

PMID:
18208877

Supplemental Content

Loading ...
Support Center